Borwin Bandelow1, Thomas Lichte2, Sebastian Rudolf3, Jörg Wiltink4, Manfred E Beutel4. 1. Department of Psychiatry and Psychotherapy, University Medical Center Göttingen. 2. Institute of General Practice, Otto-von-Guericke University Magdeburg. 3. Department of Psychiatry and Psychotherapy, University Medical Center Schleswig-Holstein, Lübeck. 4. Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz.
Abstract
BACKGROUND: Anxiety disorders (panic disorder/agoraphobia, generalized anxiety disorder, social phobia, and specific phobias) are the most common mental illnesses. For example, the 12-month prevalence of panic disorder/agoraphobia is 6%. METHOD: This guideline is based on controlled trials of psychotherapy and pharmacotherapy, retrieved by a systematic search for original articles that were published up to 1 July 2013. Experts from 20 specialty societies and other organizations evaluated the evidence for each treatment option from all available randomized clinical trials and from a synthesis of the recommendations of already existing international and German guidelines. RESULTS: 403 randomized controlled trials were evaluated. It was concluded that anxiety disorders should be treated with psychotherapy, psychopharmacological drugs, or both. Response rates to initial treatment vary from 45% to 65%. Cognitive behavioral therapy is supported by higher-level evidence than any other psychotherapeutic technique. Psychodynamic therapy is recommended as a second-line treatment. Among anxiolytic drugs, the agents of first choice are selective serotonin reuptake inhibitors and serotoninnorepinephrine reuptake inhibitors. The patient's preference should be considered in the choice of treatment. Drug treatment should be continued for 6 to 12 months after remission. If psychotherapy or drug treatment is not adequately effective, then the treatment should be switched to the other form, or to a combination of both. CONCLUSION: The large amount of data now available from randomized controlled trials permits the formulation of robust evidence-based recommendations for the treatment of anxiety disorders. Future work should more closely address the necessary duration of psychotherapy and the efficacy of combined psychotherapy and drug treatment.
BACKGROUND:Anxiety disorders (panic disorder/agoraphobia, generalized anxiety disorder, social phobia, and specific phobias) are the most common mental illnesses. For example, the 12-month prevalence of panic disorder/agoraphobia is 6%. METHOD: This guideline is based on controlled trials of psychotherapy and pharmacotherapy, retrieved by a systematic search for original articles that were published up to 1 July 2013. Experts from 20 specialty societies and other organizations evaluated the evidence for each treatment option from all available randomized clinical trials and from a synthesis of the recommendations of already existing international and German guidelines. RESULTS: 403 randomized controlled trials were evaluated. It was concluded that anxiety disorders should be treated with psychotherapy, psychopharmacological drugs, or both. Response rates to initial treatment vary from 45% to 65%. Cognitive behavioral therapy is supported by higher-level evidence than any other psychotherapeutic technique. Psychodynamic therapy is recommended as a second-line treatment. Among anxiolytic drugs, the agents of first choice are selective serotonin reuptake inhibitors and serotoninnorepinephrine reuptake inhibitors. The patient's preference should be considered in the choice of treatment. Drug treatment should be continued for 6 to 12 months after remission. If psychotherapy or drug treatment is not adequately effective, then the treatment should be switched to the other form, or to a combination of both. CONCLUSION: The large amount of data now available from randomized controlled trials permits the formulation of robust evidence-based recommendations for the treatment of anxiety disorders. Future work should more closely address the necessary duration of psychotherapy and the efficacy of combined psychotherapy and drug treatment.
Authors: A Broocks; B Bandelow; G Pekrun; A George; T Meyer; U Bartmann; U Hillmer-Vogel; E Rüther Journal: Am J Psychiatry Date: 1998-05 Impact factor: 18.112
Authors: F Jacobi; M Höfler; J Strehle; S Mack; A Gerschler; L Scholl; M A Busch; U Maske; U Hapke; W Gaebel; W Maier; M Wagner; J Zielasek; H-U Wittchen Journal: Nervenarzt Date: 2014-01 Impact factor: 1.214
Authors: David S Baldwin; Ian M Anderson; David J Nutt; Borwin Bandelow; A Bond; Jonathan R T Davidson; J A den Boer; Naomi A Fineberg; Martin Knapp; J Scott; H-U Wittchen Journal: J Psychopharmacol Date: 2005-11 Impact factor: 4.153
Authors: Ronald C Kessler; Olga Demler; Richard G Frank; Mark Olfson; Harold Alan Pincus; Ellen E Walters; Philip Wang; Kenneth B Wells; Alan M Zaslavsky Journal: N Engl J Med Date: 2005-06-16 Impact factor: 91.245
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Katharina Domschke; Christa Hohoff; Christian Jacob; Wolfgang Maier; Jürgen Fritze; Borwin Bandelow; Petra Krakowitzky; Florian Kästner; Matthias Rothermundt; Volker Arolt; Jürgen Deckert Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2008-06-05 Impact factor: 3.568
Authors: Borwin Bandelow; Joseph Zohar; Eric Hollander; Siegfried Kasper; Hans-Jürgen Möller; Joseph Zohar; Eric Hollander; Siegfried Kasper; Hans-Jürgen Möller; Borwin Bandelow; Christer Allgulander; José Ayuso-Gutierrez; David S Baldwin; Robertas Buenvicius; Giovanni Cassano; Naomi Fineberg; Loes Gabriels; Ian Hindmarch; Hisanobu Kaiya; Donald F Klein; Malcolm Lader; Yves Lecrubier; Jean-Pierre Lépine; Michael R Liebowitz; Juan José Lopez-Ibor; Donatella Marazziti; Euripedes C Miguel; Kang Seob Oh; Maurice Preter; Rainer Rupprecht; Mitsumoto Sato; Vladan Starcevic; Dan J Stein; Michael van Ameringen; Johann Vega Journal: World J Biol Psychiatry Date: 2008 Impact factor: 4.132
Authors: Michael W Collins; Anthony P Kontos; David O Okonkwo; Jon Almquist; Julian Bailes; Mark Barisa; Jeffrey Bazarian; O Josh Bloom; David L Brody; Robert Cantu; Javier Cardenas; Jay Clugston; Randall Cohen; Ruben Echemendia; R J Elbin; Richard Ellenbogen; Janna Fonseca; Gerard Gioia; Kevin Guskiewicz; Robert Heyer; Gillian Hotz; Grant L Iverson; Barry Jordan; Geoffrey Manley; Joseph Maroon; Thomas McAllister; Michael McCrea; Anne Mucha; Elizabeth Pieroth; Kenneth Podell; Matthew Pombo; Teena Shetty; Allen Sills; Gary Solomon; Danny G Thomas; Tamara C Valovich McLeod; Tony Yates; Ross Zafonte Journal: Neurosurgery Date: 2016-12 Impact factor: 4.654
Authors: Paul E Cohen; Alicia Sufrinko; Robert J Elbin; Michael W Collins; Aaron M Sinnott; Anthony P Kontos Journal: Clin J Sport Med Date: 2018-03-28 Impact factor: 3.638
Authors: Paul E Cohen; Alicia Sufrinko; Robert J Elbin; Michael W Collins; Aaron M Sinnott; Anthony P Kontos Journal: Clin J Sport Med Date: 2020-03 Impact factor: 3.454